

SATURDAY, SEPTEMBER 29, 2018

The Westin New York Grand Central • New York, NY

A Message from the Chair James Underberg, MD, FACPM, FACP, FNLA

Patients with diabetes and cardiometabolic disorders face unique challenges in their daily lives that require a focused and collaborative approach to care. Last year, at the inaugural New York Cardio-Endo-Renal Collaborative (NY CERC) we sought to facilitate the regular meeting of dedicated healthcare professionals who treat these patients.

The volume of clinical information regarding cardiometabolic disease is exploding, creating new opportunities—and new challenges—for clinicians. Understanding how this information will impact regimens and optimizing therapies for individual patients is essential.

This year, we hope to continue that conversation. At the 2nd Annual NY CERC we will once again explore the risk factors and comorbidities associated with diabetes, heart failure, dyslipidemia, atherosclerosis, as well as the impact of cardiovascular disease across all aspects of patient health. In the past year, new data and new strategies have changed the way we should approach patient care. It's time to meet again.

Please join us Saturday, September 29 in New York!

Sincerely,



James Underberg, MD, FACPM, FACP,

Immediate Past President of the National Lipid Association Clinical Assistant Professor of Medicine New York University School of Medicine New York, NY

WHAT'S INSIDE

A message from the chair	1
Benefits of attending	2
A look back at last year's meeting	2
Agenda	3

THIS YEAR'S TOPICS INCLUDE:

- Cardiovascular disease prevention
- Obesity and cholesterol management
- Strategies for chronic kidney disease
- Other cardiometabolic risk factor discussions

Final Agenda Inside!

CLICK TO REGISTER

gotoper.com/go/NYCERC18











The New York Cardio-Endo-Renal Collaborative (NY CERC) is a unique and forward-thinking conference that focuses on innovation and advancements in the cardiometabolic space. The advent of novel therapies and new technologies have changed the way we need to approach patient engagement, lifestyle medicine, and cardiovascular/metabolic disease prevention.

At last year's meeting, the **2017 NY CERC**, expert faculty delivered state-of-the-art clinical updates and strategies aimed directly at the intersection of metabolic and cardiovascular disease (CVD) prevention. More than didactic presentations, this conference is grounded in real life cases and case discussions.

PER has long been an industry leader in oncology CME, and with the second year of **NY CERC** soon to be underway, that unique and interactive approach to medical education has arrived for physicians and healthcare professionals regardless of discipline.

It's not too late to register at gotoper.com/go/NYCERC18! Can't make the live meeting? Be sure to tune into the live simulcast at gotoper.com/go/CERC18Live!

BENEFITS OF ATTENDING THIS MEETING:

- Expand your network of peers and clinical experts
- Increase your knowledge, understanding, and ability in managing cardiometabolic diseases
- Translate the latest treatment guidelines for common conditions into your practice
- Gain expert insights to overcome barriers to treatment

CHECK OUT HIGHLIGHTS FROM LAST YEAR'S MEETING To watch the full video, visit gotoper.com/go/CERC18Reel



- It's an opportunity for clinicians and researchers to come together and share and understand the newest findings in clinical research in order to provide improved services to our patients."
- This is a wonderful program. It really presents an **amalgam of experts** in the fields of cardiology, diabetes, and kidney disease."



HEAR FROM PROGRAM CHAIR DR. JAMES UNDERBERG

To watch the full video, visit gotoper.com/go/CERC18Video



We know that patients with heart failure, diabetes, those with lipid disorders, and certainly those with renal disease are at increased risk for cardiovascular events—heart attack and stroke. This daylong meeting, happening in New York, will bring in KOLs from around the country speaking on these important topics. We hope you can come!"

AGENDA - SATURDAY, SEPTEMBER 29, 2018

7:30 AM	Breakfast			
8:00 AM	Welcome and Introduction	James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA		
SESSION I: DYSLIPIDEMIA, ATHEROSCLEROSIS, CVD RISK REDUCTION, AND HEART FAILURE				
8:15 AM	The Emerging Potential for the Use of Agents Targeting Inflammation for Secondary Prevention of CVD	Paul M. Ridker, MD, MPH, FACC, FAHA		
9:00 AM	Q&A Session			
9:15 AM	Interpreting Therapeutic Advances in Heart Failure	Keith Ferdinand, MD, FACC, FAHA, FNLA, FASH		
10:00 AM	Q&A Session			
10:15 AM	Break			
10:30 AM	Improving Access to PCSK9i: Updates on Guidelines, Emerging Cardiovascular Benefits, and Overcoming Barriers to Access	James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA		
11:30 AM	Early Diagnosis of PAH to Minimize Progression of Heart Failure	Roxana Sulica, MD		
12:15 PM	Q&A Session			
12:30 PM	Non-CME Expert Theatre			
SESSION II: DIABETES, ANEMIA & CHRONIC KIDNEY DISEASE, AND VENOUS THROMBOEMBOLISM				
1:45 PM	New Development in the Treatment of Diabetes: A Guideline-Based Pharmacotherapeutic Approach to Individualizing T2DM Treatment	Helena Rodbard, MD, FACP, MACE		
2:30 PM	Q&A Session			
2:45 PM	Break			
3:00 PM	Differentiating Diagnosis and Treatment to Fit the Patient With Anemia and CKD: A Case-Based Approach	Matthew R. Weir, MD		
3:45 PM	Q&A Session			
4:00 PM	Updates on VTE Prophylaxis Therapy: DOACs and Reversal Agent	Elaine Hylek, MD, MPH		
4:45 PM	Q&A Session			
5:00 PM	Summary/Adjourn	James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA		